Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.19 USD
Change Today +0.01 / 0.85%
Volume 1.2M
CYTX On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

cytori therapeutics inc (CYTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/14 - $2.88
52 Week Low
11/12/14 - $0.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cytori therapeutics inc (CYTX) Related Bloomberg News

View More Bloomberg News

cytori therapeutics inc (CYTX) Related Businessweek News

View More BusinessWeek News

cytori therapeutics inc (CYTX) Details

Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy consisting of a heterogeneous population of specialized cells, including stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices and consumable sets, and other ancillary products for the customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions. The company markets its products to hospitals, clinics, tissue banks, and stem cell banking companies through direct sales representatives, distributors, and partners worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

78 Employees
Last Reported Date: 03/16/15
Founded in 1996

cytori therapeutics inc (CYTX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $437.4K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $79.1K
President of Asia Pacific
Total Annual Compensation: $367.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2014.

cytori therapeutics inc (CYTX) Key Developments

Cytori Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Cytori Therapeutics, Inc. filed its 10-K on Mar 16, 2015 for the period ending Dec 31, 2014. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Cytori Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for Full Year of 2015

Cytori Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported product revenues of USD 2,469,000 compared to USD 2,706,000 a year ago. Operating loss was USD 4,315,000 compared to USD 9,118,000 a year ago. Net loss allocable to common stock holders was USD 6,924,000 compared to USD 10,041,000 a year ago. Basic and diluted loss per share was USD 0.08 compared to USD 0.14 a year ago. Operating cash burn was USD 4.9 million compared to USD 9.5 million a year ago. For the twelve months, the company reported product revenues of USD 4,953,000 compared to USD 7,122,000 a year ago. Operating loss was USD 32,437,000 compared to USD 30,679,000 a year ago. Net loss allocable to common stock holders was USD 38,537,000 compared to USD 26,177,000 a year ago. Basic and diluted loss per share was USD 0.48 compared to USD 0.39 a year ago. Net cash used in operating activities were USD 30,330,000 compared to USD 34,563,000 a year ago. Purchases of property and equipment were USD 764,000 compared to USD 519,000 a year ago. Expenditures for intellectual property were USD 255,000. For the year of 2015, the company expects operating cash burn of approximately USD 25 million, product revenue expected to be within a range from USD 5 million and USD 8 million depending on developments in China, Japan and Europe, contribution (profit/loss) from sales and marketing organization, excluding share based compensation, expected to be essentially breakeven with a forecasted profit ranging from USD 100,000 and USD 300,000, and contract revenue expected to be within a range from USD 6 million and USD 8 million.

Cytori Therapeutics, Inc., Q4 2014 Earnings Call, Mar 12, 2015

Cytori Therapeutics, Inc., Q4 2014 Earnings Call, Mar 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTX:US $1.19 USD +0.01

CYTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardica Inc $0.59 USD -0.01
NeoStem Inc $2.77 USD -0.17
Nuo Therapeutics Inc $0.26 USD +0.017
Pluristem Therapeutics Inc $2.83 USD -0.03
StemCells Inc $0.99 USD +0.013
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTORI THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at